Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated <i>falciparum</i> Malaria Reduce the Risk for Recurrent New <i>falciparum</i> Infection More Than Artemether-Lumefantrine?

<table>Analysis for Dihydroartemisinin-Piperaquine versus Artemether-Lumefantrine for outcome of total treatment failure (PCR-corrected) at day 42.</table>

Malaria Research and Treatment

fig4

Figure 4

Figure 4: Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated <i>falciparum</i> Malaria Reduce the Risk for Recurrent New <i>falciparum</i> Infection More Than Artemether-Lumefantrine? 

Figure 4 | Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine? 